MediWound (MDWD) 17 May 222022 Q1 Earnings call transcript

Good day and welcome to the MediWound First Quarter 2022 Financial Results and Presentation of the EscharEx Phase 2 Clinical Trial Results Conference Call. At this time all participants are in a listen-only mode.

Following management’s prepared remarks we will hold a Q&A session. [Operator Instructions]. At this time I would like to turn the conference over to Monique Kosse of LifeSci Advisors. ahead. go Please

and press operator results Earlier MediWound today, provided Thank announcing welcome its a release corporate financial first issued a you, update. everyone. quarter and XXXX

reviewing KOLs on May release results team be We trial the Phase EscharEx issued XX, the results in which hearing two to on were of management announced will from in those U.S. addition X the XXXX. with press a

from Officer. Phase Boaz tab. Dove Lior management Rosenberg, from X releases on study. Financial investigator the website Las With You Chief Cyaandi and are Executive Wound us an Investors Dr. of Center, Ankle Board today Sharon and may Ofer both joining Also Advanced access Officer Vegas are us under company’s EscharEx Chief Gur-Lavie, Medical Malka, the Professor Gonen, the MediWound; and Officer in Member; Chief and

to begin, or Securities forward-looking to this defined Q&A Private Litigation including I the would we under of statements performance, Reform Before business everyone future like during made plans XXXX. the that are call, events or expected future relating statements session as remind Act MediWound’s future prospects,

of factors filed the that as press set notes MediWound’s SEC for forth Annual well are reasonable the such a Report forward-looking are today’s obligation with Participants upon otherwise. cautionary in the as risk the the new of forth reflected to release factors of could company expectations set directed in no outcomes uncertainties like anticipated assumptions, turn supplement Officer could to MediWound. risks results update from to to Malka, many or materially Sharon? would call At whether statements. actual result cause in assumes impact actual events, to company from or believes this Chief as due forward-looking and based the over time, are Although, Executive factors I of those beyond control information, The MediWound. Sharon the forecast any and in future the statements to statements, to that results those and forward-looking subject materially the differ differ

Monique. first our joining call you highlights. quarter and Welcome recent morning and to operational good to financial in our to those listeners Good our U.S. the Thank XXXX conference us discuss to from Israel. afternoon

and to Vegas. call pleased Q&A. and us practices. from hear Ankle Dove, discussion will in the Well all on data opinion Lior first very in key the share perspective Cya their financials Chief investigator opening the the our and Wound leaders X of Dr. pharmacology overall are with two study EscharEx call some on ask MediWound esteemed Las our for also Advanced studies and wound before today. provide from We of Rosenberg, Phase quick Medical EscharEx review we Officer Center the and They insights care principal a Boaz will trial the on that of After

next were First, safety around care significant some specialists for quarter our these leg venous before Spring effect received on the recent and and from a position EscharEx, first U.S. pleased very To top out demonstrated of data for updates the as we with primary in control of In six-month have the for which of poster in highlighted with closure SAWC the BARDA endpoints XXXX the very posters key interest and BLA XXX the The welcome interest one of XX taking a we April let our we top potential at met We to were deleterious and to was a care. high program from with a very review NexoBrid that The it would ulcers. and at which secondary recognition of approval Starting posters conference. run wound globe. was of our Phase Symposium launch of $X which wound access encouraging received the NexoBrid support protocol, the selected standard and continue warm we and bringing Study by X significant partner of data study market. in compared me clinical and NexoBrid to the a BLA supplemental expanded EscharEx. the us funding million contract, the issues And on to for EscharEx U.S. these with will XXXX. We products through observed a to ongoing arm. providing innovative results no no its process with the improvement approval over observed. of by NexoBrid current year-end a and approval. quick provide remain report NexoBrid clinical end, to U.S. anticipate positive the the dive response the for into BARDA and study and for of debridement the review forward its track KOL excited commercial of the deeper look midyear to Vericel resubmission expanded our statistically submission half were

armies for supply of Lastly have successful, solution well U.S. we of as open nonsurgical field burn care project, for to proud over the NexoBrid, This as Department the on world as development could administration. chain NexoBrid the research and Defense simplify the our treatment. the with gate project for all if are the costs started U.S. the for Army

of applications debridement. States. safety and patients, approximately debridement gel with with treated the The of at XX sites, compared primarily quick XXX VLUs call standard-of-care eight a was placebo study placebo during the adaptive with was or another The endpoint a placebo-controlled study an gel patients a XX treated as were X or to assessment evaluating key FDA. efficacy patients, debridement, Vehicle primary control care compared Gel the prospective XX complete standard a autolytic XX to compared in agreed multicenter three-month the of clinically provide enrolled with in esteemed EscharEx vehicle United clinical the days, treatment and XX enzymatic either up single vehicle The period as review handing XXX and EscharEx assessed, our incidence patients, to of of to to either of the nonsurgical control now designs Study study study, design EscharEx randomized before Phase non-surgical follow-up. results of KOL. within participants me the Let

achieve to to of complete assessed of endpoints and of reduction granulation evaluation debridement, closure assessed reduction as and vehicle of quality gel Secondary of care. enabling safety achieve time time and compared measurements. life, pain, exploratory a were wound and clinical area, benefits tissue, Incidence to wound standard both

was a for four exploratory achieved to study; the trends were or wound higher EscharEx current to for which degree study debridement autolytic guidance nine gel and enzymatic pivotal of compared our endpoints EscharEx, debridement results. pre-specified in vehicle, complete standard compared also Turning chronic parameters wound debridement least standard the of The patients debridement establish U.S. is complete treatment patients significance EscharEx This in with XX to treated eighth at of non-sharp EscharEx over XX specifically, site, treated of clear with [ph] than patients XX the out achieve to daily nonsurgical over care vehicle. with debridement The statistically XX% the of to of tissue clinical wound debridement, with to to area yet X.XXX. XX% a complete Gel demonstrating standard now for in debridement and currently study consider wound still after XX also statistical its compares of regions. require the wounds; treated of clear the time of treated four with that of of when XX Starting p-value with and treatment, had standard of secondary and X.XX. demonstrated efficacy improvement EscharEx days at and a the Vehicle. efficacy ascribed required patients weeks the days incidence XX% key met significantly with the with incidence pain important than p-value out patients significant head-to-head future The The care; complete More the median finally, compared complete metical study agent to [ph] to applications XX market Moreover, a achieved patient adder establish of was patients additional insight the nonsurgical the current significant the compared only available of vehicle, end indication to reduction And care, us of debridement patients after significantly days patients age, debridement. patients of comparison the the goals with achieved the debridement to out its improvement and of debridement this a hundreds to within to the favorable compared high on healing. year. superiority results applications generate that was XX% covariates benefit. treated with almost key complete the compared lower statistically XX can and remains above one, you of with this the achieve including significant standard by adjusting Patients and on that treated a of compared average, less about primary of estimated our standard three, of millions care for endpoint applications treated only XX with every efficacy time with efficacy to give is met that which higher the demonstrate patients of gel two, X.XXX, EscharEx period hydrogel characteristics, provides period Gel is with XX achieved Vehicle for in complete further several care, studies dollars of nonsurgical with with EscharEx on with EscharEx treated patients reduction care. baseline for assessment interest. shorter. offset to p-value granulation

and study all addition, EscharEx safety between that the tolerated showed was overall arms. the and safe well comparable was In

with adverse Importantly, of that X show time EscharEx treated there tolerability it's to With goals complete and that, the wound observed compared patients in wound for and and care. closure was well this was for treatment Phase Actually, treated additional achieved standard days with patients were EscharEx XX days differences no material debridement reported events. for safety effect for which on no to XX wound. closure estimated tolerated assess deleterious chronic to we of the study,

turn Rosenberg, paradigm. to and our please? some us need, wound unmet date, would management, to me a how product clinical Chief the Medical over debridement in of role the with the current treatment call the fit regarding evidence Professor Professor Rosenberg, robust EscharEx provide to Officer, like now generated color Let the

morning, very you everybody. Thank much, and Sharon good

study the especially, all in the partners, for thank their like staff our COVID-XX their and the and in investigative First, the families to by I would posted and pandemic. completing of commitment challenges face the the perseverance patients

considered overview pathogenic growth healthy an wound reduces with granulation tissue. tissue method used, caused reserved Efficient non-sharp chronic used reduce debridement must induce choice healing. me effectively is necrotic the a from by dependent chronic buildup Let and wound otherwise Dead or wound continual great as therefore, exposed start on may dominant There methods to tissue a reducing non-healing abnormalities unmet underlying highly regular removal causes advantages chronic with Sharp for burden and and enable that debridement. of adjusted and primarily to of a limitations. mainly start chronic ready in prompt the of debridement non-selecting during is of the nonviable debridement necrotization harbor own patient. the tissue The its repair is chronic of granulation Debridement a of spaces and each brief material wounds manner also contamination techniques or site patients of sharp The debridement to autolytic and to achieve of to necessary in are debridement. selective necrotic debride essential The is wound management. nonsurgical, to step assist ineligible debridement is role the techniques functional care, debridement wounds and in are is care an Debridement care, need debridement, be in wounds wound destruction. sharp with debridement enzymatic debridement tissue Routine acute for management. [ph]. critical wound involving stimulate and debridement. of easy-to-use, the tissue component the the and necessity

incidence compared in Vehicle. a clinical control in with and diabetes evidence, EscharEx, XX% I randomized in to the the Phase DFU, venous earlier p-value impressed higher be of in clinical was lower study, ulcer compelling EscharEx clinical with efficacy including EscharEx data diabetic to achieved EscharEx with Gel EscharEx the to in significantly BLU EscharEx. ulcer a the study a for by debridement evaluating complete shorter complete safe ulcers, patients in of continue applications. complete the versus impact within the Gel extremity doses treated with first Patients randomized Gel eight several generated ulcer patient Moving leg demonstrated with In post-traumatic wound. etiologies, debridement The significant of to tolerated effect results and EscharEx endpoints Vehicles lower foot complete on treated was and for robust X.XXX, demonstrated safety to patients date of trials. that and both the even and corroborated in compared Vehicle, of and to beneficial the The dosing XX% The achieve up leg standard time and all incidents greater treated multiple and X debridement have X number and patient's debridement and significant the life. was nonsurgical may Phase arm first higher across controlled debridement results well that's study EscharEx clinical and significantly tested to of EscharEx compared U.S. Phase from control demonstrated X applications, care. potential significant regimens. daily

incidence higher wound critical tissue wound at towards no demonstrated XX% granulation EscharEx wound preparation is healing. post bed on with which effect addition, deleterious least of In healing debridement, for

the from EscharEx average of Phase the both by and of size nonviable treatment significant two-week EscharEx data study, safe Lastly, diabetic lower XX decrease debridement leg wound wound our with daily X few period venous food and applications. ulcer during percent nonviable pharmacology significant and ulcer wound tissue end in of demonstrated debridement leg follow-up. demonstrated tissue effective the ongoing ulcer, of

debridement be for tissue improves the fits this that thus EscharEx and study need few into a of reduced treatment armamentarium journey the nonsurgical daily and potential documented a indicated to fast In [indiscernible] for topical after holds I facilitating wound chronic the addition, at X.X following wound X.X load The and and chronic debridement debridement. easy-to-use great in baseline product score post-treatment to in wound. debridement. to significant reduced It of from the market complete an our a of reduction images EscharEx unmet evaluation is to as that from rate EscharEx of samples welcome baseline effective applications, florescent addition with in after X.XX bacterial X.XX biofilm believe significantly care. contributor like for

investigator share the turn who wound Dr. over within studies, Dove, both than to with Dr. fit would Let management clinical Dove? EscharEx Phase EscharEx treated to how more product the call EscharEx patients me Cyaandi experience XX as in her like and with a X practice. current principal a

experience where It's continue morning Chief the name joining good market, have growing great options innovative still such practice, does also wound, serves we healing talking is In my that both It problem. point privilege at effective chronic wounds infections. Officer am treatment caregivers, in I burden non-healing data know, worked. on and to and local and number all for this and Doctor, society. be encouraging a A you, is everyone. basis. very as really that owner Thank Medical very the and and entry and deal on a past Wound chronic daily and disease The of My Cyaandi Nevada hands years. as huge products we and Advanced pleasure is the debilitating are wound Vegas, is a today really my It we share a call we're to clinical few EscharEx. on Dove Dr. of a physiologically. with on the our Center Ankle positive physically patients, Las treatment systemic about why new Despite and for XX in of chronic wounds with and financial the and

For first is to work, a Effective non-healing clean have debridement physiologically wound to products. effective that critical wound products preparation you order have a facilitate wound ready bed these to for in management. is for and step initially

require precise of of that and debridement, which that is via treatment to chronic why not debridement Thank speak reinforces I'm achieved to back precise, a best-in-class topical of diabetic previously, they had secondarily. all. tissue. debridement is that The foot leg the why Granulation and that traditional two the to after it to my dressings, move from turn enzymes, its you. especially data development, even have I therapy for to -- EscharEx. move a applications EscharEx on usually not or EscharEx six I a typical. venous methods, by we privilege can that level and debridement used clinical clean really of described if to opportunity is ulcers achieve close granulation wound has experience, product healthy, or appreciate with suffering encourage we bed, potential Doctor to methods long continued and several ready topical what That will belief which the cellular applications, things most replicate that available. becomes I I EscharEx enforces look uniform Sharon. As vibrant, is the robust, forward is EscharEx, today. nonsurgical is all In something and the my debridement have sharp to quite this wound hydrogels of very it or several become pressure sorry, EscharEx with We therapy you either has treating And the at to negative tissue now find achieve very other commonly ulcers to the include patients MediWound belief forward wounds. with the a time is I my

Rosenberg. much, Thank you you, Dr. thank very Dove Dr. and

chronic a manner. wounds effective, significant Your of professionals, care health the need health patients patients, can system. in wounds into care billions that millions cost and treatment a burden insight Chronic a the dollars product of annually. affect represent of and for to nonsurgical, debride the great They effectively underscores runs and prompt

excited care. forward opportunity. There undergo debridement ulcer the U.S. are are development given effect, method summary, a in and We leaving EscharEx hard-to-heal wound to two foot daily leg take about used clinical the of hundreds critical year its is patients diabetic safe that alone. debridement plan be every The bring to commercial In X venous ulcer improvement. several the with deployment and for magnitude of the of nonsurgical million can with component room hand, enzymatic show weeks debridement or millions other effective commonly year, in few autolytic much shown most we've to EscharEx, sales With every on a wounds generated yet applications. in of

for insight and we data Looking additional evidence on further parameters now to establish plans efficacy clinical can believe and benefits. development, to date study from and the provides this clinical our the generated the us Phase to better enable We the with the clinical This an design meeting file the half of second end request to that to in FDA tariff. XXXX. pivotal plan data of X

and for and to become option EscharEx millions a to the patients as FDA of clearly is are goal has become well pivotal X EscharEx from we Phase plan wounds transforming a game-changing best-in-class potential to work suffering with on potential for for debridement a a the believe positioned We as to possible. to is plan bringing soon EscharEx it committing wound Our the management. hard-to-heal establishing market. potentially therapy,

company the positioning the I Board and Ofer our have for success Boaz of my the and this accomplished my news want as and managing Gonen Ofer MediWound MediWound, of the as years the realize for the Board of and at helping transition global summary today announced long-term appointment team CEO. entire member in to company Director goal Ofer of to to company of commercial of U.S. head. new CEO and XX to opportunities experience financials, of in for for tremendous brings forward His is and process extensive more and address that lay over LifeScience the call launch advancement, as wound the future. I and our global strong lead to member, the success. the will a position a the with turning Before chapter. the strengths him pipeline continued successful and look It next than a best-in-class to investment this network, a our has strategic position portfolio businesses. potential my deep including I of I been expansion near-term in MediWound role NexoBrid, success exciting of supporting a and strong BLA the a company's in ensuring managerial product reinforcing a product, companies, experience continue on lead potential its supporting for understanding Board company our market honor is collaboration. in cusp an very alliances in phase and care. promising MediWound's The for leading of as therapy uniquely

for transformational We our and poised are positioned success for year.

please. to call Now me let Ofer, turn the

and experience to Thank tremendous you. of MediWound's next I'm the potential as support of MediWound of Officer. Thanks I and a everyone. to company. foundation look the by leading well the our Good forward driving morning, team Chief into strong grow to made phase Directors, the to Executive his has MediWound. honored global assume ongoing role Sharon excited and of biopharmaceutical Board as

to increased continue advance expand lead to value will programs to and shareholders. patient access our our our to technologies We

to Let the back call me turn Sharon.

Thank Ofer. you,

financials. the for at turn me call a Boaz? our Boaz brief look let Now to

Thank you, everyone. good Sharon, morning and

meet believe along upcoming our and This recently commercialization NexoBrid $XX BLA raised what be the effort the XX we fund, a us milestones to solid started months. have balance expected year. We million activities sheet an the We provide next and throughout to approval eventful upcoming with with net.

decrease to of was for $X.X with $X.X revenues of profit quarter a a of of profit compared was now stockpile mainly million. on statement XX% basis first revenues the period was million broader $X.X decrease equipment for Let last comparable to to This to Net period with million XXXX. primarily compared $X.X $X.X was quarter loss Operating share compared or revenues a to a the XX% emergency loss a year. product to product loss last $X.X first a gross year. per to last million XXXX compared The a of the me or fourth review $X.X fourth Total $X.X margin $X.X in the quarter. and Adjusted margin the quarter of loss from of net the of gross of loss million quarter due the million $X.X year. quarter XXXX. for million for EBITDA million of this for of per decrease was same was million $X.XX million share in BARDA. $X.XX in a related the million financial resulted same $X.X gross compared Gross

balance Moving highlights. sheet to our

As $XX.X first for of operating position XX, We our months. XXXX the and activities. cash utilizing budget, XX the March sufficient next in XXXX anticipated million. be of expected to million to on for investments activities support remained short-term were $X quarter cash is the operational Again,

Sharon? the expect to use $XX the Sharon. I over now in range conclude to million. be the of we For $XX the turn to million cash back XXXX, overview. With full that, call I year of financial will

and study their for Boaz. you, their clinical patients are Dr. is in grateful to clinical patients and we ability morning, into this it to thank of for data place us we helping participated for their morning. this investigators, thank especially, its also the I'd to real-world and KOL, like and and our joining in Naturally, time study the and Thank Rosenberg but which view objective, context ultimate practice. a the appreciate this us Dove in participation who Professor giving

are you. In positioned. well we closing, So very thank

and end approval on by of our the to track NexoBrid resubmit by BLA the midyear anticipate are continue We to year.

in to preparing level the are year continuing With the with of a call look for and to certain, Gonen to Member approval, the the smooth to We take as half path to enjoy to discuss we operator we to FDA welcoming on like of meet Board the the transition. to I Ofer second a towards clarity the EscharEx forward would questions. company and will gain turn to next and this open Operator? line success. as I the company support that, are

[Operator Instructions].

Cowen. comes with Josh Jennings question first from Our

I realizing Josh. of for is Thank Can in commitment U.S. release this for more ask of EscharEx, here strength you the looking partnership I for outside taking your for about questions. Hi, X Phase in your address X a for to your my potential assets. Phase seen the today's NexoBrid about either maybe the the guess to program? Bryan you interest press independently wanted comment data and we've or completing the plainly, the what's EscharEx given

thank Bryan you the morning to Good question. for and

I now better So we for as the are communicated next previously, of terms even think that positioned in flexibility. stage

We the injection we the had financial our injection strengthen to first or the quarter have position. cash cash in

have have line additional explore with over an or taking you. ability the alternatives collaboration. robust exploring frame This have on we any clinical other very provides with product finish providing data given you robust to opportunity all share can hand. data us I clinical current to we to establish potential explore to Now data, improvement we the that the are to It's all standard it, by all really ourselves premature now now you us as discuss Thank nonsurgical the the the of care. alternative, options which but

a for to face what timeline NexoBrid outlined that matches Class you'd you've guess typical approval thanks And I that. on X a in BLA, the Okay, resubmission.

that AdCom and potential inspections So my indicated for has readiness the Class definitively this if and a discuss such where your is if stand is, as factors panel, question that's a X with FDA you so, requested? you resubmission can the

Thanks.

that. review, Usually takes review the we either for So of two commercial inspection a in we to XXXX. on ability Europe for six-months law. which we The our the in in the mediary by the of in has launch a facilities is that COVID, But U.S., FDA being FDA and again, and it to outside half review remain facilities. and six-months the of know BLA, are on it months. get we first XXXX anticipate regarding submission the been COVID We six-month pre-approval process. speak Israel, year-end potential backlog take since by said, for of we can't in for six by NexoBrid process beginning giving encouraged the a NexoBrid That will FDA the behalf the approval and both that position inspected track the have and aware

get forward Looking while FDA we FDA. response to submit the the

As as we pre-approval for the time months resubmission, will FDA expect within acceptance XX to the get know, the FDA well Thanks. inspection. for from potential you get and -- review the we as line

Okay, you. thank

Our DeGeeter Kevin Oppenheimer. from with next question comes

I in Hey, here feedback And want for thanks taking is how first and question, patients, but his I guess adjunct understanding specifically I use all for versus know under whether better a help for used which several debridement Sharon sharp my Dr. is circumstances VLU my Q&A, we're thank for its in don't questions. debridement? nonsurgical standalone Dove an and primarily And to years. to interested as DFU

you Thank Kevin. for much the Sure. question, very

as perspective can And the You but you last provide SAWC, the a is the with from with used that Dr. -- market. audience share the in last let's and in experience. is you maintenance and conjunction fact joining go is her me up did her with available debridement, the the for nonsurgical see we conference, were I means we what Dove know about this to that debridement

with share you view can Dove, Dr. that So point? your

I Yes, can.

always but with patients who for ulcers. the had was is in parameters not this it fairly did debridement. no there private in Traditionally, I even per the sharp as some debridement EscharEx, assumptive type of wounds almost of when conjunction foot was deep we practice, So enzymatic trial, applied with in the and applied the it sharp -- clinically, diabetic debridement, the my

in I was use hope precise, again you. the precise clarification more I that sharp with my some can EscharEx, XX very much to replicate reiterate, to the of the traditional debridement by a than gives what office. blade So

I anticipate or on debridement, but the in and the you do more sharp standalone an do that, potentially debridement thus where evolution of technique? where company And and to you this the on process the most Phase maybe of and envision volume replaces care the X only I nonsurgical based guess get vision essentially nonsurgical nonsurgical patients continue earned is Dr. you. debridement surgical a reduction standard essentially debridement or the for of Dove, building mean, an data, EscharEx Thank adjunctive

for you Thank Kevin. that,

you provide can this her to we start perspective. we Dr. expect, what what So about add and know then Dove and I will

which an that the that Europe. a care, in given just for also prompt first-line Given get the we debridement, healing, U.S. the of providing of the I we was the take only preparing Papa feedback. clear say product that standard current can chance replacing well several the enzymatic was [indiscernible] comprise some dominant feedback from not effective sharp debridement, market wound by stage wound a ones therapy, the as two of the this as research And as in exactly a the bed because and of market that had market U.S. in in on effective, positioned and last this be that the the wound we given is EscharEx benchmark therapy have, as believe weeks. efficacy -- the SAWC, not research what we history used but effective. the of industry conducted got autolytic we next to we only feedback the when [ph] the believe conference EscharEx rather And was the in taking in debridement. And that And Inovoya indicated a about to and first-line is it three debrided what enzyme it things and care as mixture for proteolytic in

data products in debridement, site Dove to with to a would average Dr. We are the to share than that less I on Dr. we based call like to on now on near four application. applications, Dove. And the that, talking please, and perspective provided four the debridement turn her clinical

Yes.

in fast the private physician it like this market become as of for for is I without as product care at the large market. standalone a well that patients wound and the And think investigator speed because effective practice will EscharEx, the is that. precision and therapy be who there patients, incredibly private sees that therapy I nothing as the of incredibly who Because centers surgical treated think this debridement. a practice because trial debriding this physicians, in that the standard principal will of So was I first-line the care and were the with on think and it

will this therapy. my yes, care it of So -- standard become opinion, become in will first-line the

Thank you.

Instructions]. [Operator

He Wainwright. from comes Arthur question next with H.C. Our

the is data for Thanks everyone. robust Phase RK. And morning on good in X from This taking congratulations my Hi, for questions. Arthur the study.

So my is the doctors. first for question

the is study, in secondary important your endpoint X the and from terms Phase which perspective? view, endpoint within in exploratory more medical So is of

the regarding for Dr. Please terms secondary your meaning to you the is Dr. to Thank Thank view for endpoint question. you to share will the of call what Dove and the his of her to question Arthur. turn bed preparation. wound view in I Professor share then Rosenberg? Rosenberg

tissue bed spontaneous granulation or that is epithelization of closure say, care was we means wound that wound really and step care. it is wound shall what et but efficient tissue This saw And care this which granulation the immediate and it and can much inflammation, key step that really And longer, either by that healing the what much preparation having the will healing. kind the more, by that heal we bed what one a of for living more the we open of found, for such stand TIME, was is in the the granulation more meaning for having bit a the we kicking cetera. and faster Wound first much and the is model wound alive. is of necessary much call the we it abundant tissue cetera, treating tissue to wound take to it. et standard The than an way really means grafting

provide can Thank you, follow-up? Dr. you Rosenberg. your Dr. Dove,

really would build I what Yes. Dr. on said. Rosenberg

never that is you we a will If robust, you tissue healthy past wound stage. nothing a have that inflammatory granulation bed because do have proceed with clean not

have never decrease in will size. You a

in decrease a pain. have not will You

have quality never an life. in You'll of improvement

means healthy to can contemplate have moving to on bed before that of You have you even initial wound closure.

So in the wound the complete a my bed healthy perspective, we -- have. primary and viable most that endpoint is of the healthy getting endpoint debridement

much, very Dove. Dr. you Thank

Sharon for Thank that both. much the for you team. and And follow-up on very

related from and robust based design commentary that? could costs study Phase you. study, on on these the the guess data X I potential, So potential you Thank more the guys to pivotal the us give

question. for thank Yes, you your

of with extent of we clear discuss given data et study, terms So the as the I said, size, of not did all, development provide cetera, next of the to number of it's FDA. in that yet studies, the stage on yet fact premature first

data population, compared continue We both course, continue as to standard care. data, of and we the expect of know. others Gel We Vehicle, to you set, analyze of and analyze EscharEx provide to benefits to establish a to the will data additional robust but the

and Thank plan for the have X share Israel, data first biofilm expect load. ongoing X which from Europe to X you. and Phase in Phase current study, get data Once of in data on from the X plan where VLU pharmacology integrate the pharmacology Phase communicate you. study the from gather from study, final FDA. a also study the the also information, this with DFU, integrated course, data, that, demonstrated the the microbial U.S., and addition to want and with clarity once stage next reduction we conducted we'll all with the and establish FDA, this more We should is initial debridement the We Phase rapid we'll

my you. question. the color. you taking for Thanks for Thank Thank

to to back in this I'm showing Sharon time. the like Malka I'd closing further call no queue at questions remarks. turn for

much. look next Thank call. you. We you a to great updating on forward again our very Thank earnings Have you day.

Thank conference for concludes participating. This you call. today's

disconnect. now may You